TGF-beta Antikörper (full length)
Kurzübersicht für TGF-beta Antikörper (full length) (ABIN7879138)
Target
Alle TGF-beta (TGFb) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- full length
-
Verwendungszweck
- TGF beta 1/2/3 Antibody
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- Full length recombinant human TGF-beta2 protein was used as the immunogen for the TGF beta 1/2/3 antibody.
-
Isotyp
- IgG1, kappa
-
-
anti-TGF-beta (TGFb) antibody
TGFb Reaktivität: Human, Maus, Ratte, Kaninchen, Säugetier WB, ELISA, IHC (p) Wirt: Kaninchen Polyclonal unconjugated
anti-TGF-beta (TGFb) (AA 301-350) antibodyTGFb Reaktivität: Human, Maus, Ratte, Kaninchen, Schaf WB, ELISA, FACS, IHC (p), IF (cc), IF (p), IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
anti-TGF-beta (TGFb) antibodyTGFb Reaktivität: Human, Maus, Ratte, Rind (Kuh), Kaninchen, Schaf, Nerz, Marder WB, ELISA, FACS, IHC (p), IHC (fro) Wirt: Maus Monoclonal TB21 unconjugated
anti-TGF-beta (TGFb) antibodyTGFb Reaktivität: Human, Maus, Ratte, Rind (Kuh), Hund, Hamster, Affe ELISA, Func Wirt: Maus Monoclonal TGFB-510 unconjugated
anti-TGF-beta (TGFb) antibodyTGFb Reaktivität: Human ELISA, FACS, IHC (p), IHC (fro) Wirt: Maus Monoclonal TB21 unconjugated
-
-
Applikationshinweise
- Optimal dilution of the TGF beta 1/2/3 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot the TGF beta 1/2/3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- TGF-beta (TGFb)
-
Andere Bezeichnung
- TGF beta 1/2/3
-
Hintergrund
- This mAb recognizes TGF beta 1, 2 and 3. TGFs inhibit the growth of epithelial cells and stimulate the growth of mesenchymal cells. Most breast lesions, benign and malignant, involve abnormal proliferation and altered architecture of stromal and/or epithelial elements.
-
UniProt
- P01137
-
Pathways
- EGFR Signaling Pathway, Cellular Response to Molecule of Bacterial Origin, Stem Cell Maintenance, Glycosaminoglycan Metabolic Process, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Ribonucleoside Biosynthetic Process, Skeletal Muscle Fiber Development, Regulation of Carbohydrate Metabolic Process, Protein targeting to Nucleus
Target
-
